If you have been reading about peptide mapping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
=== Reduction of endogenous quinones === NQO1 plays a role in ubiquinone and vitamin E quinone metabolism. These quinones protect cellular membranes from peroxidative injury in their reduced state. Furthermore, reduced forms of ubiquinone and vitamin E quinone have been shown to possess antioxidant properties that are superior to their non-reduced forms.
== Properties == An Affibody molecule consists of three alpha helices with 58 amino acids and has a molar mass of about 6 kDa. A monoclonal antibody, for comparison, is 150 kDa, and a single-domain antibody, the smallest type of antigen-binding antibody fragment, 12–15 kDa. Affibody molecules have been shown to withstand high temperatures (90 °C (194 °F)) or acidic and alkaline conditions (pH 2.5 or pH 11, respectively). Affibody molecules have ashort plasma half-life because of their small size.While this is advantageous for imaging,as the unbound tracer is rapidly cleared from the bloodstream, a longer plasma half-life is generally preferred for therapeutic applications. One approach to extend the plasma half-life of small molecules, such as affibody molecules,is to link them to an albumin-binding domain (ABD). A highly effective ABD is the 46-amino acid G148-GA3 domain, which is derived from streptococcal protein G, along with its engineered variant ABD035. This version has a strong femtomolar affinity for human serum albumin (HSA) [28]. The ABD can help prolong the serum half-life by forming a complex with serum albumin (SA) in the bloodstream, increasing the size of the complex and preventing it from being filtered by the kidneys. Binders with an affinity of down to sub-nanomolar have been obtained from native library selections, and binders with picomolar affinity have been obtained following affinity maturation. Affibody molecules conjugated to weak electrophiles bind their targets covalently.
By selection of different semiconductor materials, single-color LEDs can be made that emit light in a narrow band of wavelengths, from the near-infrared through the visible spectrum and into the ultraviolet range. The required operating voltages of LEDs increase as the emitted wavelengths become shorter (higher energy, red to blue), because of their increasing semiconductor band gap.
The 2024 New Year Honours are appointments by some of the 15 Commonwealth realms to various orders and honours to recognise and reward good works by citizens of those countries. The New Year Honours are awarded as part of the New Year celebrations at the start of January and those for 2024 were announced on 29 December 2023, on the same day as the 2022 Prime Minister's Resignation Honours. The recipients of honours are displayed as they were styled before their new honour and arranged by the country whose ministers advised Charles III on the appointments, then by the honour and by the honour's grade (i.e. Knight/Dame Grand Cross, Knight/Dame Commander, etc.), and then by divisions (i.e. Civil, Diplomatic, and Military), as appropriate. The BBC reported that it had already received press releases from some recipients before the honours list was published, contrary to the "longstanding practice of modest secrecy ahead of the announcement, even though award winners will have known for weeks".
== Further reading == Lederberg, Joshua; McCray, Alexa T. (April 2, 2001). "Commentary: 'Ome Sweet 'Omics — A Genealogical Treasury of Words". The Scientist. 15 (7): 8. Retrieved 1 June 2014. Hotz, Robert Lee (13 August 2012). "Here's an Omical Tale: Scientists Discover Spreading Suffix". The Wall Street Journal.
Sources: en.wikipedia.org
In February 2019, Sergey Lavrov stated that the withdrawal from the INF Treaty would not lead to "a new Cold War". The Russian news agency TASS reported the Russian Foreign Minister Sergey Lavrov stating: "I don't think that we should talk about a new Cold War", adding that the US development of low-yield nuclear warheads (the first of which entered production in January 2019) had increased the potential for the use of nuclear weapons. Speaking to the press in Berlin on 8 November 2019, a day before the 30th anniversary of the fall of the Berlin Wall, US secretary of state Mike Pompeo warned of the dangers posed to the West by Russia and China. He said: "Today, Russia – led by a former KGB officer once stationed in Dresden [Vladimir Putin] – invades its neighbours and slays political opponents". Jonathan Marcus of the BBC opined that Pompeo "appeared to be declaring the outbreak of a second [Cold War]".
Quickly begin fermentation, out-competing other "wild yeasts" for nutrients in the must Completely utilize all fermentable sugars with a predictable sugar-to-alcohol conversion rate Have an alcohol-tolerance up to 15% or even higher depending on the winemaking style Have a high sulfur dioxide tolerance but low production of sulfur compounds such as hydrogen sulfide or dimethyl sulfide Produce a minimum amount of residual pyruvate, acetic acid and acetaldehyde Produce minimum foaming during fermentation which may create difficulties for cap management during maceration or cause bungs to pop out during barrel fermentation. Have high levels of flocculation and lees compaction that makes racking, fining and filtering of the wine easier. Inoculated (or pure cultured) yeasts are strains of Saccharomyces cerevisiae that have been identified and plated from wineries across the world (including notable producers from well-known wine regions such as Bordeaux, Burgundy, Napa Valley and the Barossa Valley).
1 μg RAE = 1 μg retinol from food or supplements 1 μg RAE = 2 μg all-trans-β-carotene from supplements 1 μg RAE = 12 μg of all-trans-β-carotene from food 1 μg RAE = 24 μg α-carotene or β-cryptoxanthin from food RAE takes into account carotenoids' variable absorption and conversion to vitamin A by humans better than and replaces the older retinol equivalent (RE) (1 μg RE = 1 μg retinol, 6 μg β-carotene, or 12 μg α-carotene or β-cryptoxanthin). RE was developed 1967 by the United Nations/World Health Organization Food and Agriculture Organization (FAO/WHO).
== Professional ventures and affiliations == Early in his career, Ariely co-founded the behavioral economics consulting firm BEworks, which was acquired by Kyu in 2017. In 2012, aspiring to develop a time management app that helps people "use time better" and avoid procrastination, Ariely co-founded Timeful with Yoav Shoham and Jacob Bank. The app was acquired by Google in 2015. In 2013, Ariely and Kristen Berman co-founded Irrational Labs, a consulting firm aimed at applying behavioral economics to consumer behavior and decision-making. In 2014, Ariely co-founded the kitchen appliance company Genie with Ayelet Carasso-Stenberg and Doron Marco. Genie manufactures a food "replicator" that cooks freeze-dried meals in cartridges. In 2015, Ariely invested in Qapital, a personal finance app, and was appointed as its chief behavioral economist. He was later named chair of the board. In 2015, Ariely gave a talk at Google about dating and relationships, discussing what women want from men, including how women's attraction to men varies depending where they are in their menstrual cycle. This was one of many talks Ariely collaborated with Google on over several years, including, for example, a talk about how people rationalize cheating. In 2016, he took on the position of chief behavioral officer at Lemonade, an insurance company that integrates aspects of behavioral economics into its insurance model. Ariely's entrepreneurial ventures also include founding Shapa in 2017, a company focused on health monitoring and behavior change.
=== Two common regimens: pens, injection ports, and pumps === One method of intensive insulinotherapy is based on multiple daily injections (sometimes referred to in medical literature as MDI). Meal insulin is supplied by injection of rapid-acting insulin before each meal in an amount proportional to the meal. Basal insulin is provided as a once or twice daily injection of dose of a long-acting insulin. In an MDI regimen, long-acting insulins are preferred for basal use. An older insulin used for this purpose is ultralente, and beef ultralente in particular was considered for decades to be the gold standard of basal insulin. Long-acting insulin analogs such as insulin glargine (brand name Lantus, made by Sanofi-Aventis) and insulin detemir (brand name Levemir, made by Novo Nordisk) are also used, with insulin glargine used more than insulin detemir. Rapid-acting insulin analogs such as lispro (brand name Humalog, made by Eli Lilly and Company) and aspart (brand name Novolog/Novorapid, made by Novo Nordisk and Apidra made by Sanofi Aventis) are preferred by many clinicians over older regular insulin for meal coverage and high correction. Many people on MDI regimens carry insulin pens to inject their rapid-acting insulins instead of traditional syringes. Some people on an MDI regimen also use injection ports such as the I-port to minimize the number of daily skin punctures. The other method of intensive/flexible insulin therapy is an insulin pump. It is a small mechanical device about the size of a deck of cards.
Sources: en.wikipedia.org
== Expression == In placental mammals, including humans, the highest levels of DAO expression are observed in the digestive tract (intestinal mucosa) and the placenta. DAO expression is also observed in kidney of various species. DAO is also expressed in eosinophils.
In that time, Stalin's centralised socialism in one country régime had negatively associated Lenin's revolutionary Bolshevism with Stalinism, i.e. government by command-policy to realise projects such as the rapid industrialisation of cities and the collectivisation of agriculture. Such Stalinism also subordinated the interests (political, national and ideological) of Asian and European communist parties to the geopolitical interests of the Soviet Union. In the 1928–1932 period of the first five-year plan, Stalin effected the dekulakisation of the farmlands of the Soviet Union, a politically radical dispossession of the kulak class of peasant-landlords from the Tsarist social order of monarchy. As Old Bolshevik revolutionaries, Bukharin, Rykov and Tomsky recommended amelioration of the dekulakisation to lessen the negative social impact in the relations between the Soviet peoples and the party, but Stalin took umbrage and then accused them of uncommunist philosophical deviations from Lenin and Marx. That implicit accusation of ideological deviationism licensed Stalin to accuse Bukharin, Rykov and Tomsky of plotting against the party and the appearance of impropriety then compelled the resignations of the Old Bolsheviks from government and from the Politburo. Stalin then completed his political purging of the party by exiling Trotsky from the Soviet Union in 1929. Afterwards, the political opposition to the practical régime of Stalinism was denounced as Trotskyism (Bolshevik–Leninism), described as a deviation from Marxism–Leninism, the state ideology of the Soviet Union.
Bibudhendra Sarkar (born August 2, 1935), commonly known as Amu Sarkar, is an Indian-born Canadian biochemist known for his research on copper-histidine therapy in human blood, which led to one of the first effective treatments for Menkes disease. From 1990 to 2002, he served as head of the Division of Biochemistry Research at the Hospital for Sick Children Research Institute in Toronto. During his tenure, he founded the institute's Department of Structural Biology Research in 1990.
=== Anti-DFS70 antibodies === Anti-DFS70 antibodies generate a dense fine speckled pattern in indirect immunofluorescence and are found in normals and in various conditions, but are not associated with a systemic autoimmune pathology. Therefore, they can be used to help to rule out such conditions in ANA positive individuals. A significant number of patients are diagnosed as systemic lupus erythematosus or undifferentiated connective tissue disease largely based on a positive ANA. In case no defined autoantibody can be detected (e.g. anti-ENA antibodies), the testing of anti-DFS70 antibodies is recommended to verify the diagnosis. Anti-DFS70 antibody tests are available as CE-marked tests. Until now, no FDA cleared assay is available.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.